News

Professor Aurélien Marabelle joins the Board of Directors of the Society for Immunotherapy of Cancer (SITC)

Professor Aurélien Marabelle, physician-scientist at Gustave Roussy, has been elected to a three-year term on the Board of Directors of the SITC, the leading international scientific society dedicated to cancer immunotherapy. His term will begin in January 2026, during the annual renewal of one-third of the board members.

Published on

Aurélien Marabelle

Professor Aurélien Marabelle, physician-scientist at Gustave Roussy, has been elected to a three-year term on the Board of Directors of the SITC, the leading international scientific society dedicated to cancer immunotherapy. His term will begin in January 2026, during the annual renewal of one-third of the board members.

Founded in 1985, the SITC is celebrating its 40th anniversary and brings together more than 2,400 experts from 42 countries. This election highlights Professor Marabelle’s pioneering role and Gustave Roussy’s commitment to therapeutic innovation. He will be the first and only French and European representative on the SITC Board.

Trained at the École Normale Supérieure de Lyon, King’s College London, and Stanford University, Professor Marabelle works at the intersection of clinical and translational research. He is an oncologist in the Department of Therapeutic Innovation and Early Trials (DITEP), Professor of Clinical Immunology at Université Paris-Saclay, and leads the INSERM Translational Research Laboratory in Immunotherapy (LRTI) at Gustave Roussy. He also coordinates the RHU (Hospital-University Research) program REMISSION, a project supported by the France 2030 plan to accelerate access to immunotherapy.

A specialist in next-generation immunotherapies, he is the author of more than 250 scientific publications and leads numerous early-phase clinical trials. He co-founded the French Society for Cancer Immunotherapy (FITC), where he currently serves as Vice-President, and sits on several international scientific committees.

“It is an honor to join the SITC Board of Directors at a strategic moment of exponential growth in immunotherapy approaches. This election commits me to promoting an ambitious scientific vision based on European academic excellence, while also fostering international collaboration, broad dissemination of knowledge, and equitable access to innovation,” he stated.

For more information

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin